Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation ...

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in ...

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec ...

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

Laxmi Patel, chief strategy officer at Savista, outlines major impacts of the “One Big Beautiful Bill” Act on Medicaid and ...

Shared decision-making helps dermatologists align treatment plans with patient needs, improving adherence and outcomes.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

A national survey finds patients want personal contact after positive cancer results, with psychosocial fears outweighing cost and transportation concerns.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...